Spark Therapeutics Inc  

(Public, NASDAQ:ONCE)   Watch this stock  
Find more results for once
+0.24 (0.44%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 54.34 - 56.24
52 week 21.20 - 70.00
Open 54.34
Vol / Avg. 0.00/658,259.00
Mkt cap 1.65B
P/E     -
Div/yield     -
EPS -2.50
Shares 30.00M
Beta     -
Inst. own 72%
Aug 3, 2016
Q2 2016 Spark Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 13, 2016
Spark Therapeutics Inc at Cantor Fitzgerald Healthcare Conference
Jun 23, 2016
Spark Therapeutics Inc at JPMorgan European Healthcare Conference
Jun 22, 2016
Spark Therapeutics Inc at ROTH Healthcare Day
Jun 13, 2016
Spark Therapeutics Inc Conference Call to Discuss Results from Ongoing Phase 1/2 Clinical Trial of SPK-9001 - Webcast
Jun 10, 2016
Spark Therapeutics Inc at Jefferies Healthcare Conference
Jun 7, 2016
Spark Therapeutics Inc at Goldman Sachs Global Healthcare Conference
May 4, 2016
Q1 2016 Spark Therapeutics Inc Earnings Release
May 4, 2016
Q1 2016 Spark Therapeutics Inc Earnings Call - Webcast
May 4, 2016
Spark Therapeutics Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1984.80% -213.59%
Operating margin -2005.01% -214.46%
EBITD margin - -206.61%
Return on average assets -31.82% -22.43%
Return on average equity -36.01% -36.28%
Employees 113 -
CDP Score - -


3737 Market St Ste 1300
United States - Map
+1-212-7906248 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington's disease, a hereditary genetic disorder.

Officers and directors

Steven M. Altschuler M.D. Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Katherine A. High M.D. President, Chief Scientific Officer, Director
Age: 63
Bio & Compensation  - Reuters
Jeffrey D. Marrazzo Chief Executive Officer, Co-Founder, Director
Age: 36
Bio & Compensation  - Reuters
Jennifer Wellman Co-Founder and Head of Regulatory Strategy
Age: 37
Bio & Compensation  - Reuters
Stephen W. Webster Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
J. Fraser Wright Ph.D. Co-Founder and Chief Technology Officer
Age: 57
Bio & Compensation  - Reuters
Joseph W. La Barge Esq. General Counsel and Head of Business Administration
Age: 43
Bio & Compensation  - Reuters
Lisa Dalton Head - Human Resources
Age: 42
Bio & Compensation  - Reuters
Diane I. Blumenthal Head of Technical Operations
Age: 56
Bio & Compensation  - Reuters
Romuald Corbau Translational Research Lead
Age: 47
Bio & Compensation  - Reuters